PUBLISHER: FirstWord Group | PRODUCT CODE: 1682206
PUBLISHER: FirstWord Group | PRODUCT CODE: 1682206
This report provides an in-depth analysis of the current landscape and future directions in the treatment of axial spondyloarthritis (axSpA), focusing on the use of biologic and pipeline therapies. It examines the use of anti-tumour necrosis factor (TNF) inhibitors as the first-line treatment following non-steroidal anti-inflammatory drugs (NSAIDs), the positioning of interleukin-17 (IL-17) inhibitors, such as Cosentyx, Taltz, and Bimzelx, and the cautious use of Janus kinase (JAK) inhibitors like Xeljanz and Rinvoq. Gain a comprehensive overview of current treatment strategies and emerging trends in axSpA management.
|
|
|
Therapy Trend reports are developed through in-depth interviews with the world's foremost Key Opinion Leaders (KOLs) on the current and future treatment landscapes in major disease areas. KOLs are carefully selected based on strict screening criteria, including their global reputation, clinical expertise, and influence within their therapeutic area. Each interview is guided by a meticulously crafted discussion guide. These guides are developed in collaboration with KOLs and peer-reviewed by industry experts to ensure that the questions are comprehensive and pertinent to current market dynamics. Through continuous market monitoring over a 12-month period following the publication of each report, we provide timely updates from KOLs on key news events, market shifts, and clinical developments.
FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.